Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor

References

• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med.338, 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet372, 293–299 (2008).
   PubMed Web of Science ®Google Scholar
• Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis.48, 831–939 (2009).
   Google Scholar
• Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob. Agents52, 1351–1358 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analysis of raltegravir for resistant HIV-1 infection. N. Engl. J. Med.359, 355–365 (2008).
   PubMed Web of Science ®Google Scholar
• Metifiot M, Marchand C, Maddali K et al. Resistance to integrase inhibitors. Viruses2, 1347–1366 (2010).
   PubMed Web of Science ®Google Scholar
• Mouscadet JF, Delelis O, Marcelin AG et al. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist. Updat.13, 139–150 (2010).
   PubMed Web of Science ®Google Scholar
• Blanco JL, Verghese V, Rhee SY et al. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis.203, 1204–1214 (2011).
   PubMed Web of Science ®Google Scholar
• Hare S, Gupta SS, Valkov E et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature464, 232–237 (2011).
   Google Scholar
• Shun MC, Raghavendra NK, Vandegraff N et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integrase. Genes Dev.21, 1767–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall HM, Ronen K, Berry C et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One2, e1340 (2007).
   PubMed Web of Science ®Google Scholar
• Hazuda DL, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science287, 646–650 (2000).
   PubMed Web of Science ®Google Scholar
• Sato M, Kawakami H, Motomura T et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type I integrase inhibitors. J. Med. Chem.52, 4869–4882 (2009).
   PubMed Web of Science ®Google Scholar
• Mathias AA, German P, Murray BP et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther.87, 322–329 (2010).
   PubMed Web of Science ®Google Scholar
• Roquebert B, Damond F, Collin G et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemoth.62, 914 (2008).
   PubMed Web of Science ®Google Scholar
• Shimura K, Kodama E, Sakagami Y et al. Broad anti-retroviral activity and resistance profile of a novel human immunodeficiency virus integrase inhibitor, elvitegravir (JTK-303/GS-9137). J. Virol.82, 764–774 (2008).
   PubMed Web of Science ®Google Scholar
• Sichtig N, Sierra S, Kaiser R et al. Evolution of raltegravir resistance during therapy. J. Antimicrob. Chemother.52, 1351–1358 (2009).
   Google Scholar
• Canducci F, Sampaolo M, Marinozzi MC et al. Dynamic pattern of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS23, 455–460 (2009).
   PubMed Web of Science ®Google Scholar
• Hatano H, Lampiris H, Fransen H et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J. Acquir. Immune Defic. Syndr.54, 389–393 (2010).
   PubMedGoogle Scholar
• Metifiot M, Vandegraaff N, Maddali K et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS25, 1175–1178 (2011).
   PubMed Web of Science ®Google Scholar
• Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J. Virol.83, 11440–11446 (2009).
   PubMed Web of Science ®Google Scholar
• Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. Infect. Drug Resist.4, 65–76 (2011).
   PubMedGoogle Scholar
• Delelis O, Malet I, Na L et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148 mutation. Nucleic Acids Res.37, 1193–1201 (2009).
   PubMed Web of Science ®Google Scholar
• Seki T, Kobayashi M, Wakasa-Morimoto C et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. Presented at: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16–19 February 2010 (Abstract 555).
   Google Scholar
• DaSilva D, Van Wesenbeeck L, Beilh D et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J. Antimicrob. Chemother65, 1262–1269 (2010).
   PubMedGoogle Scholar
• McColl DJ, Fransen S, Gupta S et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir. Ther.12, S11 (2007).
   Google Scholar
• McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antivir. Res.85, 101–118 (2010).
   PubMed Web of Science ®Google Scholar
• Kawaguchi I, Ishikawa T, Ishibashi M et al. Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006 (Abstract 580).
   Google Scholar
• German P, Warren D, Wei L et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. Presented at: 49th International Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 12–15 September 2009 (Abstract A1-1300).
   Google Scholar
• Ramanathan S, Khariton T, West S et al. Population pharmacokinetics of ritonavir-boosted elvitegravir in adult healthy subjects and HIV-infected patients. Rev. Antivir. Ther.3, 78 (2008).
   Google Scholar
• DeJesus E, Berger D, Markowitz M et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr.43, 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• German P, Warren D, West S et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J. Acquir. Immune Defic. Syndr.55, 323–329 (2010).
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P et al. Randomized, Phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS25, F7–F12 (2011).
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Berger DS, Lampiris H et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a Phase 2, randomized, controlled, dose-ranging clinical trial. J. Infect. Dis.201, 814–822 (2010).
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias AA, Hinkle J et al. Clinical pharmacology of the HIV integrase inhibitor elvitegravir. Presented at: 11th European AIDS Conference. Madrid, Spain, 24–27 October 2007 (Abstract PS 4/7).
   Google Scholar
• Molina J-M, LaMarca A, Andrade-Villanueva J et al. Elvitegravir once-daily is non-inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a Phase 3, multicenter, randomized, double blind study. Presented at: 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Rome, Italy, 17–20 July 2011 (Abstract WELBB05).
   Google Scholar
• Ramanathan S, Mathias AA, German P et al. Clinical pharmacokinetic and pharmacodynamics profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet.50, 229–244 (2011).
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Abel S, Tweedy S et al. Pharmacokinetic interactions of ritonavir-boosted elvitegravir and maraviroc. J. Acquir. Immune Defic. Syndr.53, 209–214 (2010).
   PubMedGoogle Scholar
• Ramanathan S, Shen G, Hinkle J. Pharmacokinetic evaluation of drug interactions with ritonavir-boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid-reducing agents. Presented at: 8th International Workshop on Clinical Pharmacology of HIV Therapy. Budapest, Hungary, 16–18 April 2007 (Abstract 69).
   Google Scholar
• Norvir® package insert, Abbott Laboratories, Chicago, IL, USA, revised April 2010.
   Google Scholar